{"width":"100%","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fokumi.hatenablog.com%2Fentry%2F20130409%2F1365469315\" title=\"\u4e2d\u7d76\u85ac\u306e\u65b0\u305f\u306a\u4f9b\u7d66\u6e90 - \u30ea\u30d7\u30ed\u306a\u65e5\u8a18\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","description":"\u4eca\u66f4\u3067\u3059\u304c\u3001\u6628\u5e74\u3001\u4e0b\u8a18\u306eLinepharma\u304cEU\u8af8\u56fd\u3067\u627f\u8a8d\u3092\u53d7\u3051\u305f\u3068\u3044\u3046\u8a71\u3092\u77e5\u308a\u307e\u3057\u305f\u3002\u5fd8\u5099\u9332\u3068\u3057\u3066\u30b5\u30de\u30ea\u30fc\u3060\u3051\u5f15\u7528\u3057\u3066\u304a\u304d\u307e\u3059\u3002 On 21 June 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Mifepristone Linepharma. The Agency\u2026","type":"rich","blog_title":"\u30ea\u30d7\u30ed\u306a\u65e5\u8a18","author_name":"okumi","categories":[],"title":"\u4e2d\u7d76\u85ac\u306e\u65b0\u305f\u306a\u4f9b\u7d66\u6e90","height":"190","published":"2013-04-09 10:01:55","image_url":null,"url":"https://okumi.hatenablog.com/entry/20130409/1365469315","blog_url":"https://okumi.hatenablog.com/","provider_name":"Hatena Blog","author_url":"https://blog.hatena.ne.jp/okumi/","provider_url":"https://hatena.blog","version":"1.0"}